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Makhmudbek Mallaev1,3, José A Galván1, Jennifer Amsler1, Beat Schnüriger3, Inti Zlobec1* and Daniel Inderbitzin3,4Abstract
Background and aims: Reliable prognostic markers based on biopsy specimens of colorectal cancer (CRC) are
currently missing. We hypothesize that assessment of T-cell infiltration in biopsies of CRC may predict patient
survival and TNM-stage before surgery.
Methods: Pre-operative biopsies and matched resection specimens from 130 CRC patients treated from 2002-2011
were included in this study. Whole tissue sections of biopsy material and primary tumors were immunostained for
pancytokeratin and CD8 or CD45RO. Stromal (s) and intraepithelial (i) T-cell infiltrates were analyzed for prediction
of patient survival as well as clinical and pathological TNM-stage of the primary tumor.
Results: CD8 T-cell infiltration in the preoperative biopsy was significantly associated with favorable overall survival
(CD8i p = 0.0026; CD8s p = 0.0053) in patients with primary CRC independently of TNM-stage and postoperative
therapy (HR [CD8i] = 0.55 (95% CI: 0.36-0.82), p = 0.0038; HR [CD8s] = 0.72 (95% CI: 0.57-0.9), p = 0.0049). High numbers
of CD8i in the biopsy predicted earlier pT-stage (p < 0.0001) as well as absence of nodal metastasis (p = 0.0015), tumor
deposits (p = 0.0117), lymphatic (p = 0.008) and venous invasion (p = 0.0433) in the primary tumor. Infiltration by
CD45ROs cells was independently associated with longer survival (HR = 0.76 (95% CI: 0.61-0.96), p = 0.0231) and
predicted absence of venous invasion (p = 0.0025). CD8 counts were positively correlated between biopsies and
the primary tumor (r = 0.42; p < 0.0001) and were reproducible between observers (ICC [CD8i] = 0.95, ICC [CD8s] = 0.75).
For CD45RO, reproducibility was poor to moderate (ICC [CD45i] = 0.16, ICC [CD45s] = 0.49) and correlation with
immune infiltration in the primary tumor was fair and non-significant (r[CD45s] = 0.16; p = 0.2864). For both markers,
no significant relationship was observed with radiographic T-stage, N-stage or M-stage, indicating that assessment of
T-cells in biopsy material can add additional information to clinical staging in the pre-operative setting.
Conclusions: T-cell infiltration in pre-operative biopsy specimens of CRC is an independent favorable prognostic
factor and strongly correlates with absence of nodal metastasis in the resection specimen. Quantification of CD8i is
highly reproducible and allows superior prediction of clinicopathological features as compared to CD45RO. The
assessment of CD8i infiltration in biopsies is recommended for prospective investigation.
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In solid cancers, the tumor microenvironment repre-
sents the interface between tumor, stromal and immune
cells. In 2011 Hanahan and Weinberg defined the active
evasion of cancer cells from attack and elimination by
immune cells as a newly emerging hallmark of cancer
[1]. One of the major challenges in cancer research is
the translation of knowledge from basic science into
daily diagnostic practice. In colorectal cancer (CRC), im-
munohistochemical double-staining allows an optimal
visualization of the tumor-microenvironment by using a
pancytokeratin marker for tumor cells and CD8 and
CD45RO for T-cell subtypes [2,3]. Indeed, cancer cells
involved in epithelial-mesenchymal transition (EMT) are
also known in the literature as “tumor buds” or “EMT-
like tumor cells” and represent a morphological param-
eter of tumor progression and worse survival [4-8]. In
their surroundings, T-cells are the most frequently de-
tected immune cell type with a strong evidence-based
prognostic power [3,9-12].
The tumor microenvironment is a tumor area that is
not only found at the invasive front of CRC, but also
within the main tumor body. Consequently, the micro-
environment containing intra-tumoral buds (ITB) and
T-cells can also be sampled in superficial tumor regions in
the preoperative biopsy. Importantly, the presence of ITB
in biopsies of colon and rectal cancer patients has recently
been associated with local and distant metastases [13-15].
This approach has important clinical consequences as it
allows better prediction of cancer biology already in the
preoperative setting and significantly extends the informa-
tion that can be obtained from biopsy material.
Assessment of biomarkers on biopsy material may also
provide additional independent prognostic and predict-
ive information [16]. This approach may thus aid stand-
ard radiographic and clinical staging of the CRC patient
before surgery. Consequently, we aim to address whether
the presence of CD8 and CD45RO positive T-cells in
preoperative biopsies of colon and rectal cancer is pre-
dictive of patient survival and TNM-stage thus providing
optimal support to oncologists, gastroenterologists and
surgeons in the preoperative patient management.
Methods
Patients
346 primary CRC patients surgically treated from 2002-
2011 at the Insel University Hospital (Bern, Switzerland)
were initially included in this study. A matched preopera-
tive diagnostic biopsy was available for 185 cases. An expe-
rienced gastrointestinal pathologist (AL) and two residents
(VHK and HD), blinded to the findings from the preopera-
tive biopsy reviewed all Haematoxylin and Eosin (HE)
slides from surgical resections. All resection specimens
were classified according to the TNM 7th edition. Presenceof lymphatic invasion (L), venous invasion (V), perineural
invasion (Pn), tumor grade (G), number of tumor deposits,
histological subtype and number of lymph nodes harvested
was recorded. Tumor regression grade for patients pre-
operatively treated with radio and/or chemotherapy was
graded according to recommendations by the College of
American Pathologists. Clinical data were obtained from
patient records including age at diagnosis, gender, tumor
location, clinical TNM-staging, and information on pre-
operative or postoperative therapy. Endpoints of interest
were TNM-stage and overall survival. Information on over-
all survival was available for 76 patients (median survival
73.5 months, 95% CI: 29-105). 30 patients were treated
pre-operatively and 63 received adjuvant therapy. All pre-
operative biopsies were re-reviewed. Information on the
number of biopsies per patient and the number of biopsies
containing tumor was determined.
Assay methods
Patient material was fixed in 10% buffered formalin and
paraffin-embedded at the Institute of Pathology, University
of Bern, Switzerland. Tumor blocks were sectioned at
4 μm. An immunohistochemistry double-stain for pancy-
tokeratin marker AE1/AE3 (Dako, mouse monoclonal,
1:200, enzyme pre-treatment 5 minutes; DAB chromo-
gen) and CD8 (Dako C8/144B, 1:100, pre-treatment with
Tris buffer, at 95° for 20 minutes; AEC chromogen) as
well as for AE1/AE3 and CD45RO (Abcam, 1:4000; pre-
treatment with citrate buffer, at 100° for 30 minutes; AEC
chromogen) using an automated Leica Bond III instru-
ment with Haematoxylin counterstaining was performed.
The local ethics committee of the Insel University Hos-
pital (16-03-12) approved this study.
Evaluation of immunohistochemistry
All biopsies from a single patient were first scanned at
low-power magnification (10x) and the five densest
regions of intratumoral (i) and stromal (s) CD8+ and
CD45RO+ T-cells were identified (Figure 1A). Within
these areas, CD8i, CD8s, CD45ROi, and CD45ROs T-cells
were then counted in 5 high-power fields each (HPF; 40x;
area 0.1886 mm2). The average number of infiltrating
T-cells per HPF was determined for each area and used
for statistical analysis.
Study design
This study was designed according to the REMARK
guidelines for tumor marker prognostic studies [17]. The
study design is outlined in (Figure 1B). Of the 346 pa-
tients initially identified with surgically treated primary
CRC from 2002-2011, 185 had matched preoperative bi-
opsies. Patients receiving preoperative therapy (n = 30)
were excluded from further analysis based on their small
number. Immunohistochemistry was performed on the
Figure 1 Visualization of immune infiltrates in biopsy material and study design. A: Visualization of immune infiltrates and tumor cells
by immunohistochemical double-stain for CD8 (upper panel) or CD45RO (lower panel) and pancytokeratin in biopsy material (overview x 50,
inset x 300). Stromal infiltrates are indicated by *, arrows indicate intraepithelial CD8+ or CD45RO+ T-cells. B: Study Design. 346 CRC patients were
entered into the study, 185 of which had matched biopsies. Histopathological features and clinical data were re-reviewed. Immunohistochemistry
for pancytokeratin and CD8 or CD45RO was performed. CD8+ and CD45RO+ T-cell infiltrates in biopsy specimens were evaluated in five HPF each
of stroma and neoplastic epithelium. T-cell infiltrates were analysed for prediction of patient survival and histopathologic features of the matched
resection specimen.
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had to be excluded from the study due to insufficient
invasive carcinoma remaining in the diagnostic biopsy
block. The final number of patients was 130. Patient char-
acteristics are found in (Table 1).
Statistics
The Pearson’s correlation coefficient (r) was used to de-
termine the strength of the linear relationship betweenimmune cell counts in the biopsy and resection. The
inter-observer agreement was determined using the
intraclass correlation coefficient (ICC), with values ap-
proaching 1.0 indicating improved agreement. Logistic
regression analysis was performed to calculate the prob-
ability of lymph node metastasis as a function of the num-
ber of immune cells in the biopsy. Briefly, the probability
p = e(βo+β1x)/(1- e(βo+β1x)), where βo and β1 are estimates
of the logistic equation and x is the number of immune
Table 1 Patient characteristics and association of CD8+ cells (intra- and peri-tumoral) with clinicopathological data
(max n = 130)
Feature CD8i N (%) CD8s N (%)
N (%) Low High P-value Low High P-value
Age (years) (n = 130) Median (min, max) 72 (30-91) 71.4 (30-91) 73.8 (50-90) 0.3872 72.4 (30-91) 71 (30-90) 0.876
Gender (n = 130) Male 80 (61.5) 61 (61.0) 19 (63.3) 1.0 40 (61.5) 40 (61.5) 1.0
Female 50 (38.5) 39 (39.0) 11 (36.7) 25 (38.5) 25 (38.5)
Histological subtype (n = 130) Non-mucinous 106 (81.5) 80 (80.0) 26 (86.7) 0.5923 49 (75.4) 57 (87.7) 0.1123
Mucinous 24 (18.5) 20 (20.0) 4 (13.3) 16 (24.6) 8 (12.3)
Tumour location (n = 129) Left 43 (33.3) 33 (33.3) 10 (33.3) 0.8606 21 (32.3) 22 (34.4) 0.7333
Rectum 30 (23.3) 22 (22.2) 8 (26.7) 17 (26.2) 13 (20.3)
Right 56 (43.4) 44 (44.4) 12 (40.0) 27 (41.5) 29 (45.3)
pT (n = 130) pT1 + pT2 30 (23.1) 15 (15.0) 15 (50.0) <0.0001 12 (18.5) 18 (27.7) 0.2979
pT3 + pT4 100 (76.9) 85 (85.0) 15 (50.0) 53 (81.5) 47 (72.3)
pN (n = 130) pN0 54 (41.5) 34 (34.0) 20 (66.7) 0.0015 26 (40.0) 28 (43.1) 0.8588
pN1-2 76 (58.5) 66 (66.0) 10 (33.3) 39 (60.0) 37 (56.9)
cT (n = 30) cT1-2 9 (31.0) 6 (27.3) 3 (42.9) 0.6424 5 (45.5) 4 (22.2) 0.2371
cT3-4 20 (69.0) 16 (72.7) 4 (57.1) 6 (54.6) 14 (77.8)
cN (n = 113) cN0 68 (62.4) 50 (59.5) 18 (72.0) 0.2583 32 (57.1) 36 (67.9) 0.3229
cN1-2 41 (37.6) 34 (40.5) 7 (28.0) 24 (42.9) 17 (32.1)
No. LN collected (n = 130) Median (min, max) 22 (4-73) 23.0 (6-67) 16.5 (4-73) 0.0842 23.0 (4-67) 18 (6-73) 0.1369
Tumour deposits (n = 108) 0 91 (84.3) 67 (79.8) 24 (100.0) 0.0117 42 (82.4) 49 (86.0) 0.792
≥1 17 (15.7) 17 (20.2) 0 (0.0) 9 (17.7) 8 (14.0)
Metastasis (n = 123) cM0 86 (69.9) 63 (67.0) 23 (79.3) 0.2519 42 (68.8) 44 (71.0) 0.8457
cM1 37 (30.1) 31 (33.0) 6 (20.7) 19 (31.2) 18 (29.0)
Lymphatic invasion (n = 113) L0 29 (25.7) 17 (19.3) 12 (48.0) 0.008 10 (18.5) 19 (32.2) 0.1312
L1 84 (74.3) 71 (80.7) 13 (53.0) 44 (81.5) 40 (67.8)
Venous invasion (n = 114) V0 57 (50.0) 39 (44.3) 18 (69.2) 0.0433 26 (47.3) 31 (52.5) 0.708
V1-2 57 (50.0) 49 (55.7) 8 (30.8) 29 (52.7) 28 (47.5)
Perineural invasion (n = 111) Pn0 100 (90.1) 75 (87.2) 25 (100.0) 0.0671 48 (90.6) 52 (89.7) 1.0
Pn1 11 (9.1) 11 (12.8) 0 (0.0) 5 (9.4) 6 (10.3)
Tumour grade (n = 130) G1-2 85 (65.4) 66 (66.0) 19 (63.3) 0.8286 40 (61.5) 45 (69.2) 0.3566
G3 45 (34.6) 34 (34.0) 11 (36.7) 25 (38.5) 20 (30.8)
Postoperative therapy (n = 127) None 88 (69.3) 65 (66.3) 23 (79.3) 0.2524 41 (64.1) 47 (74.6) 0.2491
Yes 39 (30.7) 33 (33.7) 6 (20.7) 23 (36.0) 16 (25.4)
MMR status (n = 117) Proficient 99 (84.6) 77 (85.6) 22 (81.5) 0.5596 52 (89.7) 47 (79.7) 0.1996
Deficient 18 (15.4) 13 (14.4) 5 (18.5) 6 (10.3) 12 (20.3)
Survival time (n = 76) Median (95% CI)
months
73.5 (29-105) 53.1 (22.6-73.9) Not reached 0.0026 26.4 (13.7-73.5) 105.4 (54.9-NE) 0.0053
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and “high” immune cell counts, we used the 50th- or
75th-percentiles. The Chi-Square or Fisher’s Exact test
was used, where appropriate. Student’s T-test was applied
for assessment of mean age differences. Univariate sur-
vival time analysis was carried out using the log-rank testand differences were plotted with Kaplan-Meier curves.
After verification of the proportional hazards assump-
tion, Cox regression analysis was performed with “low”
immune cell counts as baseline hazard of 1.0. Hazard
ratios (HR) and 95% CI were used to determine the
effect of each variable on outcome. Included in the analysis
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were considered statistically significant. No correction
for multiple comparisons was performed [18]. All ana-
lyses were carried out using SAS V9.2 (SAS Institute,
Cary, NC).
Results
T-cell infiltration in biopsies of colon and rectal cancer
Stromal CD8 T-cells were considerably more frequent
(median cell count per HPF 37.6 cells) than intrae-
pithelial CD8 infiltrates (median cell count per HPF
3.4 cells). For CD45RO, a similar pattern was observed
(median cell count CD45ROs = 56.6 cells; CD45ROi =
4.4 cells).
CD8+ and CD45RO + in the preoperative biopsy and
impact on survival- univariable
CD8+ T-cell infiltration in the preoperative biopsy was
significantly associated with favorable overall survival
independent of stromal or intraepithelial T-cell location
(CD8i, p = 0.0026; CD8s, p = 0.0053) (Figure 2A and B).
For CD45RO, only stromal infiltrates showed a favorable
association with survival time (p = 0.0031) (Figure 2C). No
association with prognosis was observed for CD45ROi
(p = 0.094) (Figure 2D).Figure 2 Prognostic effects of CD8 and CD45RO T-cell infiltration in t
pre-operative biopsy predicted a significantly prolonged survival independent
cut-off, >6.2 cells; CD8s: p = 0.0011; 50th percentile as cut-off, >37.6 cells). C, D
benefit (CD45ROs: p = 0.0031; 50th-percentile as cut-off, >56.6 cells). No signifi
(CD45ROi; p = 0.0941; 50th percentile as cut-off, > 3.4 cells).CD8+ and CD45RO + in the preoperative biopsy and
impact on survival- multivariable
The strong correlation of a greater number of CD8+ and
CD45RO+ T-cells with favorable prognosis is underlined
in multivariable analysis (Table 2). The presence of CD8i
in the biopsy maintained a significant favorable impact
on survival after adjusting for the confounding effect of
TNM-classification in the resection specimen (pT, pN,
cM) and adjuvant therapy (HR = 0.55 (95% CI: 0.36-0.82);
p = 0.0038). Similar findings were observed for CD8s
(HR = 0.72 (95% CI: 0.57-0.9); p = 0.0049) and CD45ROs
(HR = 0.76 (95% CI: 0.61-0.96); p = 0.0213). As determined
in univariable analysis, CD45ROi was not associated with
survival time in multivariable analysis.
Prediction of TNM-stage of the resection specimen based
on the evaluation of CD8+ and CD45RO+ immune infiltrates
in the preoperative biopsy
Clinicopathological associations of CD8+ and CD45RO+
T-cell infiltrates are summarized in (Table 1 and
Additional file 1: Table S1). Patients with weak CD8i infil-
tration in the biopsy frequently presented with locally ad-
vanced tumors at the time of resection (p < 0.0001). In fact,
85% (n = 85) of patients with low CD8i in the pre-operative
biopsy (<6.2 cells on average per 5 HPF; 75th percentile)he pre-operative biopsy. A, B: Strong infiltration by CD8 cells in the
of stromal or intraepithelial location (CD8i: p = 0.0026; 75th-percentile as
: Patients with strong CD45ROs infiltration derived a significant survival
cant associations with survival time were observed for CD45ROi infiltrates
Table 2 Multivariable analysis of CD8 and CD45RO with pT. pN, cM, and postoperative therapy
CD8i CD8s CD45ROi CD45ROs
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Marker Low 1.0 0.0038 1.0 0.0049 1.0 0.2644 1.0 0.0213
High 0.55 (0.36-0.82) 0.72 (0.57-0.9) 0.88 (0.71-1.1) 0.76 (0.61-0.96)
pT pT1-2 1.0 0.9525 1.0 0.4854 1.0 0.3584 1.0 0.4897
pT3-4 1.03 (0.39-2.75) 1.41 (0.54-3.67) 1.59 (0.6-4.3) 1.41 (0.53-3.72)
pN pN0 1.0 0.6523 1.0 0.7057 1.0 0.6596 1.0 0.3729
pN1-2 0.82 (0.36-1.9) 0.85 (0.37-1.95) 0.83 (0.36-1.9) 0.69 (0.3-1.6)
cM cM0 1.0 0.0683 1.0 0.0485 1.0 0.1844 1.0 0.1348
cM1 2.05 (0.95-4.4) 2.2 (1.01-4.81) 1.7 (0.78-3.7) 1.8 (0.83-3.9)
Postoperative therapy None 1.0 0.2672 1.0 0.2425 1.0 0.3805 1.0 0.4301
Yes 0.63 (0.28-1.42) 0.63 (0.29-1.37) 0.7 (0.32-1.55) 0.73 (0.33-1.6)
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ciations were observed for CD8s, CD45ROi or CD45ROs.
Radiographic T-staging was available for a subset of
patients (n = 30). As compared to pathological staging,
radiographic T-staging underestimated the anatomic extent
of the primary tumor (31% cT1/2 as compared to 6.2%
pT1/2). No correlation of T-cell infiltration with radio-
graphic T-stage was observed.
A low CD8i count in the biopsy was significantly associ-
ated with detection of positive lymph nodes (p = 0.0015)
in the resection specimen. Using the cut-off score of 6.2
cells, 66% (n = 66) of patients with low CD8i showed
lymph node positivity in comparison to 33.3% (n = 10) pa-
tients with high CD8i counts. A probability scale for pre-
dicting the risk of lymph node metastasis as a function of
CD8i infiltration is shown in (Figure 3). The more CD8i
T-cells are observed, the lower the risk of nodal metastasis.
For instance, a patient with absence of CD8i in the pre-
operative biopsy would have a 67% risk of nodal metastasis,
which decreases to 35% in a patient with 20 CD8i in the
biopsy and to only 21% when 30 CD8i are present. In prac-
tical application, this allows risk estimation of nodal metas-
tasis based on the immunohistochemical staining of a
single marker in biopsies of CRC.
Interestingly, the evaluation of CD45ROs provided
additional discriminatory information for the identifica-
tion of patients at high risk of nodal metastasis. A low
CD45ROs count (<56.6 cells) was significantly associated
with lymph node positivity (p = 0.0073) with 70.8% of pa-
tients with low CD45ROs counts (n = 46) presenting with
nodal metastasis at the time of resection as compared to
46.2% (n = 30) with strong CD45ROs infiltration (Table 3).
For 113 patients information on radiographic N-staging
from pre-operative examinations was available (Table 1
and Additional file 1: Table S1). As compared to patho-
logical staging, pre-operative radiographic staging appeared
to underestimate the frequency of nodal metastasis (37.6%cN1-2 as compared to 58.5% pN1-2). Interestingly, no cor-
relation of CD8+ or CD45RO+T-cell infiltration with
radiographic N-staging was observed. A tendency towards
a higher average number of CD8+ and CD45RO+T-cell
infiltrates was observed in biopsies from patients with ab-
sence of distant metastasis. However, the association be-
tween CD8+ or CD45RO+T-cell infiltrates in the biopsy
and absence of distant metastasis did not reach statistical
significance.
Additional prognostic factors
A greater number of CD8i T-cells in biopsy samples was
strongly predictive of the absence of lymphatic vessel inva-
sion (p = 0.008), venous vessel invasion (p = 0.433), and
absence of tumor deposits (p = 0.0117) in the resection
specimen. For CD45ROs, a significant association with ab-
sence of venous invasion (p = 0.0073) was determined. Fur-
ther, CD45ROi infiltrates were more frequently observed
in patients with mismatch-repair deficient CRC (p = 0.02).
No association of CD8i, CD8s or CD45ROs infiltration
with MMR-status was identified.
Correlation between CD8 and CD45RO immune cell
counts in biopsy and resections
Full tissue sections of primary tumors (n = 50) were evalu-
ated for CD8s and CD45ROs infiltration and were com-
pared to the matched biopsy on a case by case basis. The
correlation coefficient for CD8s was r = 0.42 (p < 0.0001)
suggesting a moderate positive relationship. For CD45ROs,
only a fair and non-significant correlation between biopsy
and resection was observed (r = 0.16; p = 0.2864).
Inter-observer agreement of CD8 and CD45RO immune
cell counts in the biopsy
The ICC was used to calculate the inter-observer agree-
ment in 50 biopsy cases for CD8i, CD8s, CD45ROi, and
CD45ROs, with values closer to 1.0 indicating stronger
Figure 3 Clinical application example. Slides are first scanned under low magnification and regions of densest CD8i T-cell infiltrates are identified.
CD8i T-cells infiltrates are then quantified in five HPF of highest density (HPF area 0.1886 mm2). The probability of lymph node metastasis can be
determined based on a nomogram of CD8i counts. The fewer T-cells in the biopsy, the greater the risk of nodal metastasis.
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indicating excellent and strong agreement, respectively. For
CD45ROi and CD45ROs, the ICC values were 0.16 and
0.49 indicating only poor to moderate agreement.
Discussion
Accurate prognostication is essential for choosing the
optimal therapeutic approach for primary CRC. Based
on the evaluation of CD8 and CD45RO infiltrates in biopsy
specimens of colon and rectal cancers, we demonstrate
prediction of patient survival, the anatomic extension of
the primary tumor, the presence of positive lymph nodes,
lymphovascular invasion, and tumor deposits. The evalu-
ation of T-cell infiltrates based on immunohistochemistry
is easy, fast and reproducible indicating usefulness in daily
diagnostic practice. Taken together, these results may im-
pact the treatment strategy for CRC patients in distinct
clinical settings.Table 3 Combination of CD8i and CD45p for prediction
of pN + (n = 130) shown are frequency (n) and column
percent (%)
CD8i neg/
CD45p neg
Only 1
positive
CD8i pos/
CD45p pos
Total P-value
pN0 11 (21.6) 31 (49.2) 12 (75.0) 54 0.0002
pN+ 40 (78.4) 32 (50.8) 4 (25.0) 76
Total 51 63 16 130First, we identify a highly significant and independent
association of CD8 and CD45ROs T-cell infiltrates in the
preoperative biopsy with patient survival after resection
of the primary tumor. This data is in consistence with
several large retrospective clinical studies including
robust multivariable analyses that have identified CD8
and CD45RO immune infiltration as central prognostic
indicator in CRC resection specimens [9,19]. The
current study now suggests that the prognostic power
of immune infiltrates in CRC can already be harnessed
in the preoperative setting. This information signifi-
cantly extends the spectrum of available preoperative
prognostic indicators based on biopsy material. In clin-
ical practice, this may provide important prognostic
information in patients receiving preoperative radio-
therapy and chemotherapy. As immune infiltrates can-
not be reliably assessed in these cases after resection,
the preoperative biopsy is critical in providing prognos-
tic information in these cases. Consequently, CRC
patients with low in-situ immune infiltration may
be considered a high risk group and may benefit from
pre-operative therapy followed by surgical resection
[20-22,16].
Second, we demonstrate that CD8i and CD45ROs im-
mune infiltration in the biopsy allows prediction of nodal
metastasis and tumor deposits in the preoperative setting.
This may provide important information to the surgeon
when deciding on the optimal strategic approach to a CRC
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a low or absent infiltration by CD8 and CD45RO T-cells
may best be managed by segmental resection due to the
significantly increased risk of lymph node metastasis [23].
Low T-cell infiltration in biopsies could therefore expand
the list of established high risk features in early CRC as de-
tailed by Quirke and colleagues in the European guidelines
for quality assurance: incomplete excision, poor differenti-
ation, lymphatic invasion, tumor budding, and venous in-
vasion [23]. To further develop this preliminary evidence,
statistically robust studies should be performed to confirm
absence of T-cell infiltration in the preoperative biopsy as a
high risk feature for early stage patients.
In patients with locally advanced operable colon can-
cer, preoperative chemotherapy is an important line of
development [22,24]. Accurate identification of nodal
positive patients is essential for patient selection. Radio-
graphic staging is standard of care in the pre-operative
setting but sub-optimal sensitivity and specificity values
for detection of nodal metastasis have been reported
[25]. Computed tomography may only correctly identify
positive lymph nodes in 45% of cases, and cut-off diame-
ters for identification of positive lymph-nodes are a matter
of debate [25,26]. In our study, radiographic staging of
locoregional nodes significantly underestimated the fre-
quency of nodal metastasis (37.6% cN1-2 as compared to
58.5% pN1-2). In this setting, assessment of T-cell infil-
trates in biopsy specimens may provide additional valuable
information on the relative risk for nodal metastasis.
Third, the preoperative estimation of tumor stage may
also assist in planning the optimal surgical approach in
locally advanced colon and rectal cancer. We demon-
strate that patients with low CD8i infiltration in the bi-
opsy are at high risk of transmurally invasive primary
tumors with lymphovascular invasion, spread to local
lymph nodes and formation of tumor deposits in the
pericolic tissue. In colon cancer, extensive lymph node
removal by resection in the mesocolonic plane should be
advocated to reduce the relative risk of tumor recur-
rence and improve long term survival for these patients
[27-29]. In rectal cancer, pre-operative staging has pro-
found therapeutic implications. Early stage patients may
be treated by radiotherapy alone while locally advanced
or nodal-positive patients may be treated with chemother-
apy or radiotherapy before resection [30]. In addition to
radiographic staging, low immune infiltration may indicate
the need for a risk-adapted therapeutic approach taking
into consideration an elevated risk of lateral lymph node
metastasis, deep tumor infiltration, and presence of tumor
deposits.
The present study has several strengths. First, we pro-
vide a novel approach for prognostication of CRC pa-
tients in the preoperative setting based on a robust and
well-established biomarker. The prognostic value of CD8infiltration in primary CRC has been established in nu-
merous large and statistically robust studies and this
marker is included as central feature in the immuno-
score consortium led by the Society for Immunotherapy
of Cancer (SITC) [31]. Second, our analysis is based on a
well-characterized cohort with complete follow-up in-
cluding CRC patients of all stages. Third, this study is
designed in accordance with the REMARK guidelines
for tumor marker prognostic studies including assess-
ment of inter-observer reproducibility [17]. Based on the
superior reproducibility and prognostic value of CD8
over CD45RO as a biomarker, we provide a specific prac-
tical approach requiring immunostaining of a single slide
for CD8 infiltrates followed by quantification of T-cell
infiltrates in five HPF of highest density. CD8 infiltrates
may also be efficiently evaluated using bioinformatics ap-
proaches saving time in the manual assessment of slides
[9]. Consequently, evaluation of this single marker by im-
munohistochemistry in biopsies is a promising method of
risk prediction in daily diagnostic practice.
Weaknesses of the study include the limited sample
size involving only a relatively small cohort of rectal can-
cer cases. Cut off levels for T-cell infiltration may be in-
fluenced by the inherent characteristics of the study
collective. Consequently, we recommend prospective in-
vestigation and external validation of the prognostic value
of CD8+ and CD45RO+ immune infiltrates in biopsy spec-
imens on independent cohorts.
Conclusions
Assessment of T-cell infiltration in preoperative biopsies
provides additional independent prognostic information
for CRC patients. Quantification of CD8i T-cell infiltrates
may aid standard radiographic and clinical staging of the
primary tumor and provide information on the relative risk
for nodal metastasis before surgery. Evaluation of CD8i in-
filtration by immunohistochemistry is highly reproducible
and shows superior potential as a prognostic marker in
comparison to CD45RO. The assessment of CD8i T-cell
infiltration in biopsies is recommended for prospective
investigation.
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